APO Research
Talk to an analyst

APO RESEARCH · REPORT

Injectable HIV Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Injectable HIV Treatment Market Outlook and Growth Opportunities 2026

29 December 2025190 pages

Choose your research edition.

Industry ResearchInjectable HIV Treatment Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Injectable HIV Treatment Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Injectable HIV Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Injectable HIV Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Injectable HIV Treatment Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Injectable HIV Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Injectable HIV Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Injectable HIV Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Injectable HIV Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Injectable HIV Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Injectable HIV Treatment market include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Injectable HIV Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Injectable HIV Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Injectable HIV Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Injectable HIV Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Injectable HIV Treatment Segment by Company

Theratechnologies

ViiV Healthcare

Gilead Sciences

Janssen Pharmaceuticals

Injectable HIV Treatment Segment by Type

Cabotegravir

Lenacapavir

Rilpivirine

Ibalizumab

Other

Injectable HIV Treatment Segment by Application

Pre-Exposure Prophylaxis

HIV Treatment

Injectable HIV Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Injectable HIV Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Injectable HIV Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Injectable HIV Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Injectable HIV Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable HIV Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Injectable HIV Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable HIV Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Injectable HIV Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Injectable HIV Treatment industry.

Chapter 3: Detailed analysis of Injectable HIV Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Injectable HIV Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Injectable HIV Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Injectable HIV Treatment Industry Trends Table 2. Injectable HIV Treatment Industry Drivers Table 3. Injectable HIV Treatment Industry Opportunities and Challenges Table 4. Injectable HIV Treatment Industry Restraints Table 5. Global Injectable HIV Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Injectable HIV Treatment Revenue Share by Company (2021-2026) Table 7. Global Injectable HIV Treatment Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Injectable HIV Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Injectable HIV Treatment Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Injectable HIV Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Injectable HIV Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Injectable HIV Treatment Company, Product Type & Application Table 13. Global Injectable HIV Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Injectable HIV Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cabotegravir Table 18. Significant Companies of Lenacapavir Table 19. Significant Companies of Rilpivirine Table 20. Significant Companies of Ibalizumab Table 21. Significant Companies of Other Table 22. Global Injectable HIV Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Injectable HIV Treatment Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Injectable HIV Treatment Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Injectable HIV Treatment Sales Volume Share by Type (2021-2026) Table 26. Global Injectable HIV Treatment Sales Volume Share by Type (2027-2032) Table 27. Global Injectable HIV Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Injectable HIV Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Injectable HIV Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Injectable HIV Treatment Sales Value Share by Type (2021-2026) Table 31. Global Injectable HIV Treatment Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Pre-Exposure Prophylaxis Table 33. Significant Companies of HIV Treatment Table 34. Global Injectable HIV Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Injectable HIV Treatment Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Injectable HIV Treatment Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Injectable HIV Treatment Sales Volume Share by Application (2021-2026) Table 38. Global Injectable HIV Treatment Sales Volume Share by Application (2027-2032) Table 39. Global Injectable HIV Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Injectable HIV Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Injectable HIV Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Injectable HIV Treatment Sales Value Share by Application (2021-2026) Table 43. Global Injectable HIV Treatment Sales Value Share by Application (2027-2032) Table 44. Global Injectable HIV Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Injectable HIV Treatment Sales by Region (2021-2026) & (K Units) Table 46. Global Injectable HIV Treatment Sales Market Share by Region (2021-2026) Table 47. Global Injectable HIV Treatment Sales by Region (2027-2032) & (K Units) Table 48. Global Injectable HIV Treatment Sales Market Share by Region (2027-2032) Table 49. Global Injectable HIV Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Injectable HIV Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Injectable HIV Treatment Sales Value Share by Region (2021-2026) Table 52. Global Injectable HIV Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Injectable HIV Treatment Sales Value Share by Region (2027-2032) Table 54. Global Injectable HIV Treatment Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Injectable HIV Treatment Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Injectable HIV Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Injectable HIV Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Injectable HIV Treatment Sales by Country (2021-2026) & (K Units) Table 59. Global Injectable HIV Treatment Sales Market Share by Country (2021-2026) Table 60. Global Injectable HIV Treatment Sales by Country (2027-2032) & (K Units) Table 61. Global Injectable HIV Treatment Sales Market Share by Country (2027-2032) Table 62. Global Injectable HIV Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Injectable HIV Treatment Sales Value Market Share by Country (2021-2026) Table 64. Global Injectable HIV Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Injectable HIV Treatment Sales Value Market Share by Country (2027-2032) Table 66. Theratechnologies Company Information Table 67. Theratechnologies Business Overview Table 68. Theratechnologies Injectable HIV Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Theratechnologies Injectable HIV Treatment Product Portfolio Table 70. Theratechnologies Recent Development Table 71. ViiV Healthcare Company Information Table 72. ViiV Healthcare Business Overview Table 73. ViiV Healthcare Injectable HIV Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. ViiV Healthcare Injectable HIV Treatment Product Portfolio Table 75. ViiV Healthcare Recent Development Table 76. Gilead Sciences Company Information Table 77. Gilead Sciences Business Overview Table 78. Gilead Sciences Injectable HIV Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Gilead Sciences Injectable HIV Treatment Product Portfolio Table 80. Gilead Sciences Recent Development Table 81. Janssen Pharmaceuticals Company Information Table 82. Janssen Pharmaceuticals Business Overview Table 83. Janssen Pharmaceuticals Injectable HIV Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolio Table 85. Janssen Pharmaceuticals Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. Injectable HIV Treatment Distributors List Table 89. Injectable HIV Treatment Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Injectable HIV Treatment Product Image Figure 2. Global Injectable HIV Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Injectable HIV Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Injectable HIV Treatment Sales (2021-2032) & (K Units) Figure 5. Global Injectable HIV Treatment Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Injectable HIV Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cabotegravir Image Figure 10. Lenacapavir Image Figure 11. Rilpivirine Image Figure 12. Ibalizumab Image Figure 13. Other Image Figure 14. Global Injectable HIV Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Injectable HIV Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Injectable HIV Treatment Sales Volume Share by Type (2021-2032) Figure 17. Global Injectable HIV Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Injectable HIV Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Injectable HIV Treatment Sales Value Share by Type (2021-2032) Figure 20. Pre-Exposure Prophylaxis Image Figure 21. HIV Treatment Image Figure 22. Global Injectable HIV Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Injectable HIV Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Injectable HIV Treatment Sales Volume Share by Application (2021-2032) Figure 25. Global Injectable HIV Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Injectable HIV Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Injectable HIV Treatment Sales Value Share by Application (2021-2032) Figure 28. Global Injectable HIV Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Injectable HIV Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Injectable HIV Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Injectable HIV Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Injectable HIV Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. North America Injectable HIV Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Injectable HIV Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Injectable HIV Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Injectable HIV Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Injectable HIV Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Injectable HIV Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. South America Injectable HIV Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Injectable HIV Treatment Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Injectable HIV Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Injectable HIV Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Injectable HIV Treatment Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Injectable HIV Treatment Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Cabotegravir
  • Lenacapavir
  • Rilpivirine
  • Ibalizumab
  • Other
Applications
  • Pre-Exposure Prophylaxis
  • HIV Treatment
Companies covered
  • Theratechnologies
  • ViiV Healthcare
  • Gilead Sciences
  • Janssen Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Injectable HIV Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Injectable HIV Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Injectable HIV Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Injectable HIV Treatment Market Dynamics
  1. 2.1 Injectable HIV Treatment Industry Trends
  2. 2.2 Injectable HIV Treatment Industry Drivers
  3. 2.3 Injectable HIV Treatment Industry Opportunities and Challenges
  4. 2.4 Injectable HIV Treatment Industry Restraints
3 Injectable HIV Treatment Market by Company
  1. 3.1 Global Injectable HIV Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Injectable HIV Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Injectable HIV Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Injectable HIV Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Injectable HIV Treatment Company Ranking (2024-2026)
  6. 3.6 Global Injectable HIV Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Injectable HIV Treatment Company Product Type and Application
  8. 3.8 Global Injectable HIV Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Injectable HIV Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Injectable HIV Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Injectable HIV Treatment Market by Type
  1. 4.1 Injectable HIV Treatment Type Introduction
  2. 4.1.1 Cabotegravir
  3. 4.1.2 Lenacapavir
  4. 4.1.3 Rilpivirine
  5. 4.1.4 Ibalizumab
  6. 4.1.5 Other
  7. 4.2 Global Injectable HIV Treatment Sales Volume by Type
  8. 4.2.1 Global Injectable HIV Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Injectable HIV Treatment Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Injectable HIV Treatment Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Injectable HIV Treatment Sales Value by Type
  12. 4.3.1 Global Injectable HIV Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Injectable HIV Treatment Sales Value by Type (2021-2032)
  14. 4.3.3 Global Injectable HIV Treatment Sales Value Share by Type (2021-2032)
5 Injectable HIV Treatment Market by Application
  1. 5.1 Injectable HIV Treatment Application Introduction
  2. 5.1.1 Pre-Exposure Prophylaxis
  3. 5.1.2 HIV Treatment
  4. 5.2 Global Injectable HIV Treatment Sales Volume by Application
  5. 5.2.1 Global Injectable HIV Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Injectable HIV Treatment Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Injectable HIV Treatment Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Injectable HIV Treatment Sales Value by Application
  9. 5.3.1 Global Injectable HIV Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Injectable HIV Treatment Sales Value by Application (2021-2032)
  11. 5.3.3 Global Injectable HIV Treatment Sales Value Share by Application (2021-2032)
6 Injectable HIV Treatment Regional Sales and Value Analysis
  1. 6.1 Global Injectable HIV Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Injectable HIV Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Injectable HIV Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Injectable HIV Treatment Sales by Region (2027-2032)
  5. 6.3 Global Injectable HIV Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Injectable HIV Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Injectable HIV Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Injectable HIV Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Injectable HIV Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Injectable HIV Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Injectable HIV Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Injectable HIV Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Injectable HIV Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Injectable HIV Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Injectable HIV Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Injectable HIV Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Injectable HIV Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Injectable HIV Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Injectable HIV Treatment Sales Value Share by Country, 2025 VS 2032
7 Injectable HIV Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Injectable HIV Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Injectable HIV Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Injectable HIV Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Injectable HIV Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Injectable HIV Treatment Sales by Country (2027-2032)
  6. 7.4 Global Injectable HIV Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Injectable HIV Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Injectable HIV Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Injectable HIV Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Injectable HIV Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Injectable HIV Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Theratechnologies
  2. 8.1.1 Theratechnologies Company Information
  3. 8.1.2 Theratechnologies Business Overview
  4. 8.1.3 Theratechnologies Injectable HIV Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Theratechnologies Injectable HIV Treatment Product Portfolio
  6. 8.1.5 Theratechnologies Recent Developments
  7. 8.2 ViiV Healthcare
  8. 8.2.1 ViiV Healthcare Company Information
  9. 8.2.2 ViiV Healthcare Business Overview
  10. 8.2.3 ViiV Healthcare Injectable HIV Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ViiV Healthcare Injectable HIV Treatment Product Portfolio
  12. 8.2.5 ViiV Healthcare Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Injectable HIV Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Injectable HIV Treatment Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Janssen Pharmaceuticals
  20. 8.4.1 Janssen Pharmaceuticals Company Information
  21. 8.4.2 Janssen Pharmaceuticals Business Overview
  22. 8.4.3 Janssen Pharmaceuticals Injectable HIV Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolio
  24. 8.4.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Injectable HIV Treatment Value Chain Analysis
  2. 9.1.1 Injectable HIV Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Injectable HIV Treatment Sales Mode & Process
  6. 9.2 Injectable HIV Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Injectable HIV Treatment Distributors
  9. 9.2.3 Injectable HIV Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst